SAB Biotherapeutics Inc

Stock Chart, Company Information, and Scan Results

$2.26(as of Jul 30, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

SAB Biotherapeutics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$2.26
Ticker SymbolSABS
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees63
CountyUSA
Market Cap$23.5M
EBIDTA-38.7M
10-Day Moving Average2.59
P/E Ratio-0.61
20-Day Moving Average2.43
Forward P/E Ratio0.00
50-Day Moving Average2.06
Earnings per Share-3.70
200-Day Moving Average2.42
Profit Margin-Infinity%
RSI47.80
Shares Outstanding9.3M
ATR0.44
52-Week High5.01
Volume216,579
52-Week Low1.00
Most Recent Support Level2.25
Book Value21.4M
Most Recent Resistance Level2.85
P/B Ratio0.98
Upper Keltner3.43
P/S Ratio55.70
Lower Keltner1.43
Debt-to-Equity Ratio3.43
Next Earnings DateUnknown
Cash Surplus-4.0M
Next Ex-Dividend DateUnknown

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical trials in delaying the onset or progression of type 1. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

SAB Biotherapeutics Inc In Our Stock Scanner

As of Jul 30, 2025
example chart graphic
Scan Name: Bull FlagScan Type: Chart Pattern Scans
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.